Sareum’s small molecule drug discovery expertise builds value by developing drug candidates, focused on cancer and autoimmune disease, for licencing to pharmaceutical and biotechnology companies.
08 January 2021
07 January 2021
15 December 2020
15 December 2020
The potential of Sareum's SDC-1801 TYK2/JAK1 inhibitor in the fight against Covid-19
IMC Full Year Results, Oct 2020 (Slides)
Proactive Investors, Aug 2020 (Video)
BIO Digital, June 2020 (Slides)
BioTrinity, April 2020 (Video, Slides)
Sareum Limited
Unit 2A, Langford Arch
London Road, Pampisford
Cambridge CB22 3FX
United Kingdom
tel: +44 (0) 1223 497700
fax: +44 (0) 1223 497701
